目的 探討復(fù)方苦參注射液聯(lián)合FOLFOX4化療方案治療胃癌患者的臨床療效及對外周血Th和Tc漂移的影響。方法 2013年7月—2014年1月襄陽市中心醫(yī)院收治的晚期胃癌患者86例,隨機(jī)分對照組和治療組,每組43例。兩組患者均采用FOLFOX4方案化療。治療組在此基礎(chǔ)上每個化療周期1～10 d靜脈滴注復(fù)方苦參注射液,20 mL加入250 mL生理鹽水,1次/d。2周為1個化療周期,兩組患者均連續(xù)治療2個周期后評價療效。同時比較兩組患者外周血Th、Tc漂移情況。結(jié)果 治療后,對照組和治療組總有效率分別為55.81%、69.77%,兩組比較差異有統(tǒng)計學(xué)意義(P < 0.05)。兩組患者Th1、Th1/Th2、Tc1、Tc1/Tc2均顯著升高,同組治療前后差異有統(tǒng)計學(xué)意義(P < 0.05);且治療后治療組Th1、Th2、Th1/Th2、Tc1、Tc1/Tc2高于對照組,兩組比較差異有統(tǒng)計學(xué)意義(P < 0.05)。治療后,治療組IFN-γ、IL-4、IL-10、TNF-α均明顯改善,對照組僅IL-4、TNF-α改善,同組治療前后差異有統(tǒng)計學(xué)意義(P < 0.05);且治療后治療組IFN-γ、IL-4、IL-10、TNF-α改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計學(xué)意義(P < 0.05)。對照組和治療組不良反應(yīng)發(fā)生率分別為60.46%、34.88%,兩組比較差異具有統(tǒng)計學(xué)意義(P < 0.05)。結(jié)論 復(fù)方苦參注射液聯(lián)合FOLFOX4化療方案治療胃癌具有較好的臨床療效,可明顯提高患者的機(jī)體免疫功能,值得臨床推廣應(yīng)用。

Objective To investigate the effect of Compound Kushen Injection combined with FOLFOX4 chemotherapy in treatment of advanced gastric cancer and peripheral blood Th and Tc drift. Methods The patients with advanced gastric cancer (86 cases) of Xiangyang Central Hospital were randomly divided into control and treatment groups, and each group had 43 cases. The patients in two groups were treated FOLFOX4 chemotherapy. The patients in treatment group were iv administered with Compound Kushen Injection at days 1－10 of each chemotherapy cycle, 20 mL adding 250 mL saline, once daily. A cycle of chemotherapy included 2 weeks, and the efficacy was evaluated after two cycles of treatment. At the same time, peripheral blood Th and Tc drift situation were compared between two groups. Results After treatment, the efficacies in the control and treatment groups were 55.81% and 69.77%, respectively, and there were differences between two groups (P < 0.05). Th1, Th1/Th2, Tc1, and Tc1/Tc2 in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, Th1, Th2, Th1/Th2, Tc1, Tc1/Tc2 in the treatment group were higher than those in the control group, with significant difference between two groups (P < 0.05). IFN-γ, IL-4, IL-10, and TNF-α in treatment group were significantly improved, while IL-4 and TNF-α in the control group improved, and the difference was statistically significant in the same group (P < 0.05). IFN-γ, IL-4, IL-10, and TNF-α in treatment group improved better than those of control group, with significant difference between two groups (P < 0.05). The incidence of adverse reactions in the control and treatment groups were 60.46% and 34.88%, respectively, and there were differences between two groups (P < 0.05). Conclusion Compound Kushen Injection combined with FOLFOX4 chemotherapy has the good clinical effect in treatment of advanced gastric cancer, and can obviously improve the immune function, which is worth clinical promotion.